Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy

被引：24

作者：

Bijlsma, Johannes W. J. ^{[1
]}

van der Goes, Marlies C. ^{[1
]}

Hoes, Jos N. ^{[1
]}

Jacobs, Johannes W. G. ^{[1
]}

Buttgereit, Frank ^{[1
]}

Kirwan, John ^{[1
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, NL-3508 GA Utrecht, Netherlands

来源：

NEUROENDOCRINE IMMUNOLOGY IN RHEUMATIC DISEASES: TRANSLATION FROM BASICS TO CLINICS | 2010年 / 1193卷

关键词：

glucocorticoids; DMARDs; rheumatoid arthritis; EULAR guidelines; JOINT DESTRUCTION; PREDNISOLONE; TRIAL; BENEFITS;

D O I：

10.1111/j.1749-6632.2009.05342.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucocorticoids (GCs) are used extensively in patients with rheumatoid arthritis (RA). Recent data on the efficacy of these drugs in alleviating symptoms of inflammation, but also in retarding erosive damage, are presented. In addition, a critical review of the rather limited literature on adverse effects of chronic use of low dose GCs is given. It becomes clear that the net effect of low-dose GCs in the treatment of rheumatoid arthritis favors the beneficial aspects of these drugs above the negative aspects. Prudent use of GCs can be recommended.

引用

页码：123 / 126

页数：4

共 16 条

[1] [Anonymous], COCHRANE DATABASE SY
[2] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
Boers, M
Verhoeven, AC
Markusse, HM
vandeLaar, MAFJ
Westhovens, R
vanDenderen, JC
vanZeben, D
Dijkmans, BAC
Peeters, AJ
Jacobs, P
vandenBrink, HR
Schouten, HJA
vanderHeijde, DMFM
Boonen, A
vanderLinden, S
[J]. LANCET, 1997, 350 (9074) : 309 - 318
[3] Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial
Capell, HA
Madhok, R
Hunter, JA
Porter, D
Morrison, E
Larkin, J
Thomson, EA
Hampson, R
Poon, FW
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (07) : 797 - 803
[4] Criswell LA, 2000, COCHRANE DB SYST REV, V2
[5] Safety of low dose glucocorticoid treatment in rheumatoid arthritis:: published evidence and prospective trial data
Da Silva, JAP
Jacobs, JWG
Kirwan, JR
Boers, M
Saag, KG
Inês, LBS
de Koning, EJP
Buttgereit, F
Cutolo, M
Capell, H
Rau, R
Bijlsma, JWJ
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (03) : 285 - 293
[6] Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study
Hafstroem, I.
Albertsson, K.
Boonen, A.
van der Heijde, D.
Landewe, R.
Svensson, B.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) : 508 - 513
[7] A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects
Hansen, M
Podenphant, J
Florescu, A
Stoltenberg, M
Borch, A
Kluger, E
Sorensen, SF
Hansen, TM
[J]. ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 (11) : 713 - 718
[8] EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
Hoes, J. N.
Jacobs, J. W. G.
Boers, M.
Boumpas, D.
Buttgereit, F.
Caeyers, N.
Choy, E. H.
Cutolo, M.
Da Silva, J. A. P.
Esselens, G.
Guillevin, L.
Hafstrom, I.
Kirwan, J. R.
Rovensky, J.
Russell, A.
Saag, K. G.
Svensson, B.
Westhovens, R.
Zeidler, H.
Bijlsma, J. W. J.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (12) : 1560 - 1567
[9] Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis
Hoes, J. N.
Jacobs, J. W. G.
Verstappen, S. M. M.
Bijlsma, J. W. J.
Van der Heijden, G. J. M. G.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (12) : 1833 - 1838
[10] Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo
Jacobs, JWG
van Everdingen, AA
Verstappen, SMM
Bijlsma, JWJ
[J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1422 - 1428

← 1 2 →